Opendata, web and dolomites

MiRCHOL SIGNED

Mechanistic and therapeutic implications of microRNA deregulation for drug resistance in bile duct cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MiRCHOL project word cloud

Explore the words cloud of the MiRCHOL project. It provides you a very rough idea of what is the project "MiRCHOL" about.

successful    orchestrating    mirs    70    dismal    cholangiocarcinoma    last    disease    gt    patient    consequence    mir    urgently    ing    unclear    supervise    expression    molecular    mortality       genes    editing    alone    characterization    transcriptomes    completion    matched    translational    insights    chemoresistance    cancers    micrornas    incidence    medicine    besides    outcome    limited    vast    transferable    complicating    clinical    progression    deregulation    linking    efficacy    scientific    myself    plus    world    yield    multiple    instability    modulate    hepatobiliary    resistance    independent    reflecting    drug    stage    dr    me    data    pathogenesis    society    emphasized    therapy    patients    expand    treatment    expertise    chemoresistant    metastasis    37    doubled    cancer    deregulated    unresectable    expert    survival    involvement    researcher    diagnosis    genome    achievement    options    skills    integrate    regulate    heterogeneity    andersen    liver    crispr    pattern    genomic    rate    cca    tumor    hence   

Project "MiRCHOL" data sheet

The following table provides information about the project.

Coordinator
KOBENHAVNS UNIVERSITET 

Organization address
address: NORREGADE 10
city: KOBENHAVN
postcode: 1165
website: www.ku.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 200˙194 €
 EC max contribution 200˙194 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2020-07-23

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) coordinator 200˙194.00

Map

 Project objective

Cholangiocarcinoma (CCA) is a dismal type of liver cancer which incidence has more than doubled the last 20 years and mortality rate in Europe alone increased 37%, reflecting the limited treatment options. In >70% of patients CCA is unresectable due to advanced stage of disease at diagnosis, resulting in a 5% 5-year survival rate. CCA is characterized by molecular and clinical heterogeneity, complicating therapy and assessment of drug efficacy. Tumor heterogeneity is emphasized in limited response of therapy (drug resistance) and besides genomic instability a likely consequence of deregulated pathways under control of microRNAs (miRs). Each miR can regulate multiple genes/pathways, directly linking them to tumor heterogeneity. Deregulation of miRs can cause/control chemoresistance in other cancers, but in CCA their role is yet unclear. Thus, detailed characterization of miRs in CCA, focusing on their impact in drug resistance is urgently needed. Hence, I have 3 specific aims of this proposal: to 1) characterize the deregulated expression pattern of miRs involved in CCA pathogenesis and integrate this data with transcriptomes obtained from matched patients; 2) determine the role of deregulated miRs in control of chemoresistance, and 3) modulate by genome-editing key deregulated miR(s) targeting chemoresistant genes using the novel `CRISPR-Mir’ method. Achievement of these aims will yield key new insights into the role of miRs in orchestrating CCA progression and metastasis, as well as their involvement in drug resistance. My findings will have an impact on the society and in particular in patient outcome. Dr. Andersen, a world-wide expert in the molecular pathogenesis of CCA with a vast experience in genome medicine, will supervise the project. Successful completion of this proposal will enable me to expand my scientific expertise (plus technical and transferable skills) and to establish myself as an independent researcher in hepatobiliary and translational research.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MIRCHOL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MIRCHOL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

POMOC (2019)

Charles IV and the power of marvellous objects

Read More  

iRhomADAM (2020)

Uncovering the role of the iRhom2-ADAM17 interaction in inflammatory signalling

Read More